Figure 1
ASC stemness potential in endometriosis-like lesions. (A) Multicolor flow cytometry analysis of cells in the plot of singlet cells based on staining for CD105, CD29, Sca-1, and CD45. The percentages of mesenchymal stem cells, including early passage (3rd passage) adipose tissue-derived stem cells (ASCs), and late passage (20th passage) ASCs, harboring the cell-surface expression markers CD29, Sca-1, and CD105, and negative CD45 are shown. (B) Changes in secondary morphology of endometriosis-like lesion configuration after treatment with ASCs. Control intravenous administration of only PBS on day 1, E-ASCs-D1 intravenous administration of early passage ASCs on day 1, L-ASCs-D1 intravenous administration of late passage ASCs on day 1, E-ASCs-D15 intravenous administration of early passage ASCs on day 15, E-ASCs-D15 intravenous administration of late passage ASCs on day 15. Mice were sacrificed on day 28. n = 10 per group. Data are presented as the mean ± standard error. *P < 0.05 vs. Control.
